• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Gap between patients with schizophrenia and their psychiatrists on the needs to psychopharmacological treatment: A cross-sectional study.精神分裂症患者及其精神科医生在精神药理学治疗需求上的差距:一项横断面研究。
Neuropsychopharmacol Rep. 2020 Sep;40(3):232-238. doi: 10.1002/npr2.12118. Epub 2020 Jun 3.
2
[Psychiatrists' decision making and monitoring of antipsychotic prescription for elderly schizophrenia patients].[精神科医生对老年精神分裂症患者抗精神病药物处方的决策与监测]
Encephale. 2016 Apr;42(2):124-9. doi: 10.1016/j.encep.2015.05.004. Epub 2016 Jan 12.
3
Schizophrenia patients' and psychiatrists' perspectives on ethical aspects of symptom re-emergence during psychopharmacological research participation.精神分裂症患者及精神科医生对参与精神药理学研究期间症状复发伦理问题的看法。
Psychopharmacology (Berl). 2003 Dec;171(1):58-67. doi: 10.1007/s00213-002-1160-9. Epub 2003 May 17.
4
A comparison of patients' and prescribers' beliefs about neuroleptic side-effects: prevalence, distress and causation.患者与开处方者对抗精神病药物副作用的看法比较:患病率、痛苦程度及成因
Acta Psychiatr Scand. 1998 Jan;97(1):93-7. doi: 10.1111/j.1600-0447.1998.tb09969.x.
5
Psychiatrists' attitudes to maintenance medication for patients with schizophrenia.精神科医生对精神分裂症患者维持用药的态度。
Psychol Med. 2003 Jan;33(1):83-9. doi: 10.1017/s0033291702006797.
6
Substance abuse and the management of medication nonadherence in schizophrenia.精神分裂症中的物质滥用与药物治疗依从性管理
J Nerv Ment Dis. 2006 Jun;194(6):454-7. doi: 10.1097/01.nmd.0000221289.54911.63.
7
Antipsychotic use in patients with schizophrenia treated in private psychiatry.私立精神病学机构中接受治疗的精神分裂症患者使用抗精神病药物的情况。
Swiss Med Wkly. 2005 Feb 19;135(7-8):109-15. doi: 10.4414/smw.2005.10727.
8
[Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].[使用长效注射用利培酮的基本原理:法国精神科医生的一项调查]
Encephale. 2013 May;39 Suppl 1:S8-14. doi: 10.1016/j.encep.2012.03.005. Epub 2013 Mar 28.
9
Clinical implications of the CATIE schizophrenia trials: day-to-day management lessons for Australasian psychiatrists.CATIE精神分裂症试验的临床意义:给澳大利亚和新西兰精神科医生的日常管理经验教训
Australas Psychiatry. 2007 Dec;15(6):465-9. doi: 10.1080/10398560701689186.
10
Patient characteristics, burden and pharmacotherapy of treatment-resistant schizophrenia: results from a survey of 204 US psychiatrists.治疗抵抗性精神分裂症患者的特征、负担和药物治疗:来自对 204 名美国精神科医生的调查结果。
BMC Psychiatry. 2019 Nov 14;19(1):362. doi: 10.1186/s12888-019-2318-x.

引用本文的文献

1
Awareness and management of cognitive impairment associated with schizophrenia in psychiatrists and patients: Results from a cross-sectional survey.精神科医生和患者对精神分裂症相关认知障碍的认识与管理:一项横断面调查结果
Schizophr Res Cogn. 2025 Jun 27;42:100375. doi: 10.1016/j.scog.2025.100375. eCollection 2025 Dec.
2
Impact of clozapine once-daily versus multiple-daily dosing regimen on relapse in patients with treatment-resistant schizophrenia: A 1-year retrospective cohort study.氯氮平每日一次与每日多次给药方案对难治性精神分裂症患者复发的影响:一项为期1年的回顾性队列研究。
Psychopharmacology (Berl). 2025 Jan;242(1):161-171. doi: 10.1007/s00213-024-06658-x. Epub 2024 Aug 6.
3
Corrigendum.勘误
Neuropsychopharmacol Rep. 2020 Dec;40(4):427. doi: 10.1002/npr2.12148.

本文引用的文献

1
Patients' Knowledge about Prescribed Antipsychotics and Medication Adherence in Schizophrenia: A Cross-Sectional Survey.精神分裂症患者对抗精神病药物的认知和用药依从性:一项横断面调查。
Pharmacopsychiatry. 2017 Nov;50(6):264-269. doi: 10.1055/s-0043-113828. Epub 2017 Jul 4.
2
Patients' Preferences Related to Benefits, Risks, and Formulations of Schizophrenia Treatment.患者对精神分裂症治疗的益处、风险和制剂的偏好。
Psychiatr Serv. 2015 Jul;66(7):719-26. doi: 10.1176/appi.ps.201400188. Epub 2015 Mar 16.
3
The VAGUS insight into psychosis scale--self-report and clinician-rated versions.迷走神经洞察精神病量表——自我报告版和临床医生评定版
Psychiatry Res. 2014 Dec 30;220(3):1084-9. doi: 10.1016/j.psychres.2014.08.005. Epub 2014 Aug 19.
4
Impact of once- versus twice-daily perphenazine dosing on clinical outcomes: an analysis of the CATIE data.帕利哌酮一日一次与一日两次给药对临床结局的影响:对 CATIE 数据的分析。
J Clin Psychiatry. 2014 May;75(5):506-11. doi: 10.4088/JCP.13m08695.
5
Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis.抗精神病药物与安慰剂治疗精神分裂症复发的比较:系统评价和荟萃分析。
Lancet. 2012 Jun 2;379(9831):2063-71. doi: 10.1016/S0140-6736(12)60239-6. Epub 2012 May 3.
6
The influence of therapeutic alliance and insight on medication adherence in schizophrenia.治疗联盟和领悟对精神分裂症患者药物依从性的影响。
Nord J Psychiatry. 2012 Feb;66(1):49-54. doi: 10.3109/08039488.2011.598556. Epub 2011 Aug 10.
7
Patient's trust in their psychiatrist: a cross-sectional survey.患者对精神科医生的信任:一项横断面调查。
Eur Arch Psychiatry Clin Neurosci. 2011 Dec;261(8):603-8. doi: 10.1007/s00406-011-0199-1. Epub 2011 Mar 3.
8
Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis.低剂量与标准剂量抗精神病药预防精神分裂症复发的Meta 分析。
Schizophr Bull. 2011 Jul;37(4):788-99. doi: 10.1093/schbul/sbp149. Epub 2009 Nov 27.
9
Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia.长效注射用利培酮的每月给药及纹状体多巴胺D2受体占有率用于精神分裂症的治疗
J Clin Psychiatry. 2008 Aug;69(8):1281-6. doi: 10.4088/jcp.v69n0811.
10
A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA).阿立哌唑用于普通精神科实践中精神分裂症或分裂情感性障碍患者管理的前瞻性、多中心、随机、平行组、开放标签研究:阿立哌唑广泛有效性试验(BETA)
Schizophr Res. 2006 May;84(1):77-89. doi: 10.1016/j.schres.2005.12.857. Epub 2006 Feb 14.

精神分裂症患者及其精神科医生在精神药理学治疗需求上的差距:一项横断面研究。

Gap between patients with schizophrenia and their psychiatrists on the needs to psychopharmacological treatment: A cross-sectional study.

机构信息

Department of Psychiatry, Saiseikai Central Hospital, Tokyo, Japan.

Department of Psychiatry, Ohizumi Hospital, Tokyo, Japan.

出版信息

Neuropsychopharmacol Rep. 2020 Sep;40(3):232-238. doi: 10.1002/npr2.12118. Epub 2020 Jun 3.

DOI:10.1002/npr2.12118
PMID:32489004
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7722670/
Abstract

AIM

Psychopharmacological treatment is indispensable in patients with schizophrenia but data on needs, preferences, and complaints about their medications are limited. Moreover, there has been no study to assess the degree of awareness of their psychiatrists (gap in needs) regarding these issues.

METHODS

Ninety-seven Japanese patients with schizophrenia (ICD-10) were asked to fill in the questionnaire consisting of multiple-choice questions regarding (a) their needs and complaints about psychopharmacological treatment that they were receiving, and (b) their preference of dosage form, dosing frequency, and timing of dosing. Additionally, their psychiatrists in charge were asked to predict their patients' response to the above questions.

RESULTS

Both the most frequently endorsed need and complaints about the current psychopharmacological treatment were "nothing in particular" (n = 14, 16.7% and n = 17, 20.2%); merely 23.1% and 15.4% of their psychiatrists correctly predicted these responses, respectively. "Once a day" (n = 56, 65.1%), "at bedtime" (n = 53, 61.6%), and "tablet" (n = 51, 59.3%) were the patients' most favorite dosing frequency, timing, and dosage form, respectively; 59.8% (n = 49), 54.9% (n = 45), and 64.6% (n = 53) of their psychiatrists predicted them.

CONCLUSIONS

These findings suggest that there is substantial room for improvement on the side of psychiatrists to capture their patients' needs and complaints about psychopharmacological treatment.

摘要

目的

精神分裂症患者的精神药理学治疗不可或缺,但有关其药物治疗需求、偏好和用药相关问题的资料有限。此外,目前尚无研究评估精神科医生对这些问题的认识程度(需求差距)。

方法

97 例日本精神分裂症患者(ICD-10)填写了一份包含多项选择题的问卷,内容涉及他们正在接受的精神药理学治疗的需求和用药相关问题(a),以及他们对剂型、给药频率和给药时间的偏好(b)。此外,还要求他们的主管精神科医生预测患者对上述问题的反应。

结果

目前精神药理学治疗中最常被认可的需求和用药相关问题都是“没什么特别的”(n=14,16.7%和 n=17,20.2%);仅有 23.1%和 15.4%的精神科医生正确预测了这些反应。“每天一次”(n=56,65.1%)、“睡前”(n=53,61.6%)和“片剂”(n=51,59.3%)是患者最喜爱的给药频率、时间和剂型,分别有 59.8%(n=49)、54.9%(n=45)和 64.6%(n=53)的精神科医生预测到了这些结果。

结论

这些发现表明,精神科医生在了解患者对精神药理学治疗的需求和用药相关问题方面有很大的改进空间。